Bristol-Myers
Squibb Company (NYSE:BMY) today announced that its Board of
Directors has elected Karen Vousden, Ph.D., to the Board, effective
January 1, 2018. Dr. Vousden will serve as a member of the Science and
Technology Committee of the Board of Directors.
Dr. Vousden, 60, is currently group leader at the Francis Crick
Institute in London and the Chief Scientist at Cancer Research UK, where
she is responsible for focusing on the role of basic science in the
treatment of cancer. She brings to the Board more than 30 years of
experience leading groundbreaking cancer research, having served in her
current role since 2016 and in the role of Director of the Beatson
Institute for Cancer Research from 2002 to 2016. She also held
leadership roles at the National Cancer Institute from 1995 to 2002. She
has served on the Board of the American Association for Cancer Research.
"Karen is a world class cancer researcher and a highly accomplished
leader in her field,” said Giovanni
Caforio, M.D., chairman and chief executive officer, Bristol-Myers
Squibb. “Her understanding of cancer biology and immunology research
will bring valuable insights to advancing our strategy and strong
pipeline in oncology along with our broader pipeline of transformational
medicines.”
“Karen brings to the Board deep scientific expertise developed through a
successful career in research, including her current leadership role at
one of the world’s most influential cancer research organizations,” said
Vicki L. Sato, Ph.D., lead independent director, Bristol-Myers Squibb.
“Karen’s focus on cancer biology and translational medicine lend an
important perspective to the Board and we look forward to her
contributions.”
“Bristol-Myers Squibb has been at the forefront of researching and
developing new therapies that harness the immune system to fight
cancer,” said Dr. Vousden. “It’s a tremendous honor to be appointed to
the Board, and I look forward to working with Giovanni, his leadership
team and the rest of the Board during this unprecedented moment in
cancer research.”
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information about
Bristol-Myers Squibb, visit us at BMS.com
or follow us on LinkedIn,
Twitter,
and YouTube.
Bristol-Myers Squibb Media: Laura Hortas, 609-252-4587 laura.hortas@bms.com orKen Dominski, 609-252-5251 ken.dominski@bms.com or Investors: Tim Power, 609-252-7509 timothy.power@bms.com orBill Szablewski, 609-252-5894 william.szablewski@bms.com